Evidence map›Paper›PMID 27585789›Full record

ArticleCancer immunology, immunotherapy : CII2016

The role of Ly49E receptor expression on murine intraepithelial lymphocytes in intestinal cancer development and progression.

Aline Van Acker, Els Louagie, Jessica Filtjens, Sylvie Taveirne, Els Van Ammel, Tessa Kerre, Dirk Elewaut, Tom Taghon, Bart Vandekerckhove, Jean Plum and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Aline Van AckerDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, 9000, Ghent, Belgium.ORCID 0000-0002-8347-1750
Els LouagieDepartment of Rheumatology, Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center, Ghent University, Ghent, Belgium.
Jessica FiltjensDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, 9000, Ghent, Belgium.
Sylvie TaveirneDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, 9000, Ghent, Belgium.
Els Van AmmelDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, 9000, Ghent, Belgium.
Tessa KerreDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, 9000, Ghent, Belgium.
Dirk ElewautDepartment of Rheumatology, Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center, Ghent University, Ghent, Belgium.
Tom TaghonDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, 9000, Ghent, Belgium.
Bart VandekerckhoveDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, 9000, Ghent, Belgium.
Jean PlumDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, 9000, Ghent, Belgium.
Georges LeclercqDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, 9000, Ghent, Belgium. georges.leclercq@ugent.be.
Ghent University · BEGhent University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ly49E is a member of the Ly49 family of NK receptors and is distinct from other members of this family on the basis of its structural properties, expression pattern and ligand recognition. Importantly, Ly49E receptor expression is high on small intestinal and colonic intraepithelial lymphocytes (IELs). Intestinal IELs are regulators of the mucosal immune system and contribute to front-line defense at the mucosal barrier, including anti-tumor immune response. Whereas most Ly49 receptors have MHC class-I ligands, we showed that Ly49E is instead triggered by urokinase plasminogen activator (uPA). uPA has been extensively implicated in tumor development, where increased uPA expression correlates with poor prognosis. As such, we investigated the role of Ly49E receptor expression on intestinal IELs in the anti-tumor immune response. For this purpose, we compared Ly49E wild-type mice to Ly49E knockout mice in two established tumor models: Apc

Indexed as

Adenomatous Polyposis Coli ProteinAnimalsAzoxymethaneCarcinogenesisCarcinoma in SituDisease Models, AnimalEpitheliumGene Expression Regulation, NeoplasticImmunity, CellularIntestinal NeoplasmsLymphocytesMiceMice, Inbred StrainsMice, KnockoutNK Cell Lectin-Like Receptor Subfamily ATumor BurdenAdenomatous Polyposis Coli Proteinadenomatous polyposis coli protein, mouseAzoxymethaneKlra5 protein, mouseNK Cell Lectin-Like Receptor Subfamily AUrokinase-Type Plasminogen ActivatorIntestinal cancerIntraepithelial lymphocyteLy49EUrokinase plasminogen activator

Identifiers

PMID27585789
PMCPMC11029008
OpenAlexW2509067389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.